Monthly Archives: September 2014

Aug. 6, 2014

Colleagues of Yoshiki Sasai, leading Japanese life science researcher, say he has taken his own life; Sasai was co-author of discredited stem cell study published in journal Nature that was retracted due to factual errors and allegations of misconduct. MORE

Journal Nature retracts two scientific papers it published that initially electrified biologists by describing easy way to make stem cells; says papers were error-filled and had not been verified by anyone else. MORE

Op-Ed article by evolutionary geneticist Svante Paabo warns against using sequenced genomes of Neanderthals to re-create Neanderthal individuals; contends from an ethical perspective such an idea should be condemned, and argues that using stem cells to create cells and tissues in test tubes for research is far more ethically defensible and technically feasible. MORE

Scientists, reporting in journal Cell Stem Cell, move step closer to goal of creating stem cells perfectly matched to a patients DNA in order to treat diseases; say they have created patient-specific cell lines for 'therapeutic cloning' out of skin cells of two adult men. MORE

Japanese research institute concludes that study published in journal Nature that was once hailed as breakthrough in creating stem cells contains fabricated and doctored images that cast doubt on its findings; singles out study's lead author Haruko Obokata, stem cell biologist, saying she had altered or misrepresented illustrations in her research papers. MORE

Japanese research institute acknowledges that study billed as breakthrough in stem cell research contained spliced image, material recycled from lead author's doctoral thesis, and other mistakes; disclosure threatens to discredit newly acclaimed researcher Haruko Obokata, whose team found that simple acid bath might turn cells in the body into stem cells; findings appeared in journal Nature. MORE

Teruhiko Wakayama, one of the authors of startling study that claimed to have found a simple way to make stem cells, says he is no longer sure of its conclusions; calls for its retraction. MORE

Study published in journal Nature finds that simple acid bath might turn out to be quicker and easier source of multipurpose stem cells than methods now in use; technique was developed by researchers at Riken Center for Developmental Biology in Kobe, Japan, and Brigham and Womens Hospital and Harvard Medical School in Boston MORE

Stem cell clinics in United States and Mexico, like Regenerative Medicine Institute in Tijuana, are offering unproven stem cell treatments for high price to desperate clients, posing challenge for scientists who are moving cautiously and seeking more data; efficacy and safety of such treatments remains in question. MORE

Read more from the original source:
Stem Cells - The New York Times

SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on the Company's website,www.novogen.com.

For more information please contact:

Corporate Contact

Media enquiries

Executive Chairman & CEONovogen GroupGraham.Kelly@novogen.com+61 (0) 2 9472 4100

In the USA:

Read the original post:
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference